Previous close | 19.40 |
Open | 19.40 |
Bid | 19.50 x 0 |
Ask | 20.00 x 0 |
Day's range | 19.40 - 19.70 |
52-week range | 14.20 - 20.40 |
Volume | |
Avg. volume | 10 |
Market cap | N/A |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | 24 Oct 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
DENVER, September 26, 2024--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, is scheduled to report its third quarter 2024 financial results after the close of trading on the New York Stock Exchange on Thursday, October 24, 2024.
Interest rate-sensitive REITs (Real Estate Investment Trusts) are set to benefit from the Federal Reserve's anticipated easing of monetary policy. Richard Anderson, Wedbush managing director of equity research for REITs, joins Catalysts to provide insights into this segment of the market. Anderson observes an "instant gratification" scenario unfolding in REITs, noting their quick recovery despite the weaker state of the 10-year Treasury yield (^TNX). He explains that "any kind of investment vehicle with an income component like the REITs" tends to thrive in a declining rate environment. However, he raises questions about the longer-term outlook, wondering, "What does a better rate environment, a normal sloping yield curve, do to people's attention of the fundamentals of commercial real estate?" describing this as "the next leg of opportunity" for the sector. Anderson points out that uncertainty within the 10-year yield curve affects REITs' ability to deploy capital and grow earnings. He emphasizes, "The real thing that we're watching is the longer end of the curve. And if we get some certainty there, then it's perhaps off to the races, and perhaps we'll have an outperformance here in 2024 from the REITs." Watch the video above to hear what Anderson thinks are the most attractive investment opportunities in REITs. For more expert insight and the latest market action, click here to watch this full episode of Catalysts. This post was written by Angel Smith
Healthpeak (DOC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).